Medfree Inc.
Newark, CA
- UEI
- R4V7MLYWDUN5
- CAGE
- 7XAX6
- Primary NAICS
- 339112 Surgical and Medical Instrument Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 9165 Rudder Wy, Newark, CA 94560, USA
- Website
- medfreeinc.com
- Industry
-
- Health Care
- Health Care Equipment & Services
- Health Care Providers & Services
- SIC code
- 38 Instruments & Related Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
About the company
Medfree Inc. is a minority-owned small business registered with SAM.gov since June 14, 2017, specializing in innovative cardiovascular medical devices. The company focuses on developing minimally invasive solutions for heart valve repair, particularly addressing mitral and tricuspid valve regurgitation. Medfree's core competency lies in creating novel transcatheter devices that aim to improve upon existing technologies in the structural heart market. Their approach involves leveraging proven techniques such as transcatheter edge-to-edge repair (TEER) while developing simpler, more user-friendly systems that can be deployed through smaller catheter sizes.
Through federal grant awards, Medfree Inc. has received support for multiple projects in cardiovascular device development. The National Heart, Lung, and Blood Institute (NHLBI) has funded Medfree's work on a novel 12F self-closing mitral valve repair system for percutaneous treatment of moderate to severe mitral regurgitation. This project, supported by grants R43HL147825 and R44HL147825, aims to improve upon the current market-leading MitraClip device. Additionally, the National Science Foundation (NSF) has awarded Medfree a Small Business Innovation Research (SBIR) Phase I grant under the Technology, Innovation, and Partnerships program to develop a transcatheter device for tricuspid valve repair. This project focuses on creating a low-profile catheter and implant device that can be deployed via jugular vein access, addressing the unique challenges presented by the tricuspid valve's anatomy. Both NHLBI and NSF grants support Medfree's efforts in preclinical testing, design validation, and progression towards human clinical trials, ultimately aiming to commercialize these innovative cardiac devices and address significant unmet needs in the percutaneous structural heart market.
Quick answers
Is Medfree Inc. registered in SAM.gov?
Yes. Medfree Inc.'s SAM.gov registration is active through July 4, 2027.
What is Medfree Inc.'s most recent federal award?
Medfree Inc.'s most recent federal grant award is Novel self-closing 12F mitral valve repair system to percutaneously treat moderate to severe regurgitation using… (SB1HL174244), from National Heart Lung and Blood Institute (NIH), on April 1, 2024.
On GovTribe
See Medfree Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors